Skip to content
DataLookout
Menu

NCT07549464

Phase I Study Of PLM-102 In Patients With Relapsed And Refractory Acute Myeloid Leukemia

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 7 versions: 3 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Oct 1, 2026 to Aug 20, 2026
    • Site details revised
  2. Notable Eligibility criteria expanded, about 24 words
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year

Arms and interventions

Dose Escalation of PLM-102Experimental

Treatment will be adminstered on an outpatient basis

Drugs: PLM-102

Sites

1 site in 1 country

  • UT MD AndersonHouston, Texas, United States